8C99C7EA.png
  • GV-971
    • Product overview
    • China Phase III Clinical Trial
    • Mechanism of Action
    • Clinical Guideline
    • Q&A
  • Scientific Research Information
    • GREEN MEMORY
    • Post-marketing Study
    • IIR Program
    • Relevant Literature
  • Information and Services
    • Master e-Classes
    • Typical Case
    • Case Study
    • Assessment Scale
    • Conference Information
    • News Reports
    • Pharmacovigilance
  • Company Website
CN
8C99C7EA.png
CN
  • GV-971
    • Product overview
    • China Phase III Clinical Trial
    • Mechanism of Action
    • Clinical Guideline
    • Q&A
  • Scientific Research Information
    • GREEN MEMORY
    • Post-marketing Study
    • IIR Program
    • Relevant Literature
  • Information and Services
    • Master e-Classes
    • Typical Case
    • Case Study
    • Assessment Scale
    • Conference Information
    • News Reports
    • Pharmacovigilance
  • Company Website
021-50540520
pvg-banner-423.png banph3-268.jpg

Information and Services

INFORMATION

  • GREEN MEMORY
  • Post-marketing Study
  • IIR Program
  • Relevant Literature
Relevant Literature
GREEN MEMORY
Post-marketing Study
IIR Program
Relevant Literature
Your location:
  • Home
  • Scientific Research Information
  • Relevant Literature

Published regularly, each issue of Cognition • Focus analyzes hot topics in the field of cognitive neuroscience, and intensively focuses on the latest research progress of brain-gut axis and Alzheimer's disease.

All
2022
2021
Issue 5
Issue 4
Issue 3
Issue 2
Issue 1
2021 Issue 2
Chapter I: Interpretation of Progress in Research on Alzheimer's Disease
  • 1. Alzheimer’s Disease
  • 2. Prevalence, Risk Factors, and Management of Dementia and Mild Cognitive Impairment in Adults Aged 60 Years or Older in China: A Cross-Sectional Study
  • 3. The Cost of Alzheimer's Disease in China and Re-Estimation of Costs Worldwide
  • 4. 2021 Alzheimer's Disease Facts and Figures
  • 5. Chapter Review and Commentary
Chapter II: Interpretation of Phase II-III Clinical Study of Sodium Oligomannate
  • 1. A Phase-II Randomized Trial of Sodium Oligomannate in Alzheimer's Dementia
  • 2. A 36-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase-3 Clinical Trial of Sodium Oligomannate for Mild-to-Moderate Alzheimer's Dementia
  • 3. Chapter Review and Commentary

Read more

  • GV-971

    New hope for treating Alzheimer's disease worldwide

    img1.jpg
    webcode.png
  • Contact us

    Address: 421 Newton Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China

    Phone: 021-50540520

  • Quick Links
    • Home
    • Contact Us
    • Scientific Research Information
    • Pharmacovigilance
    • News Reports
    • Company Website

Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

The information on this website is provided as knowledge only and shall not replace medical advice and medical consultation provided by physicians or other qualified healthcare professionals. The information on this website shall not be used for disease diagnosis.

©2022 GreenValley Inc.beian.png 沪公网安备31011502018352号沪ICP备2021021810号-3  Powered by Yongsy

Copyright Notice Legal Notices Terms of use